Managing unwanted immunogenicity of biologicals

Autoimmunity Reviews

Volumn 14, Issue 7, 2015, Pages 569-574

  Deehan, Maureen ^a   Garcês, Sandra ^b,c   Kramer, Daniel ^d   Baker, Matthew P ^e   Rat, Dorothea ^f   Roettger, Yvonne ^f   Kromminga, Arno ^g,h  

^a NOVIMMUNE SA   (Switzerland)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

^d Industriepark Höchst   (Germany)

^e Antitope Ltd   (United Kingdom)

^f Industriepark Höchst   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h IPM BIOTECH GmbH   (Germany)

Author keywords

Adalimumab; Anti drug antibodies; Biological drugs; Etanercept; Immunogenicity; Infliximab; Therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BETA INTERFERON; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; CD4+ T LYMPHOCYTE; DRUG MONITORING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PROTEIN PROCESSING; REVIEW; ANIMAL MODEL; ANTIBODY PRODUCTION; DRUG DEVELOPMENT; DRUG HYPERSENSITIVITY; IMMUNOGENETICS; IMMUNOLOGY;

ANTIBODIES; ANTIBODY FORMATION; DRUG DISCOVERY; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGENETIC PHENOMENA; MODELS, ANIMAL;

EID: 84928926117     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.02.007     Document Type: Review

References (73)

1. FDA Guidance for industry. Assay development for immunogenicity testing of therapeutic proteins Available from. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf.
2. FDA Immunogenicity assessment for therapeutic protein products - guidance for industry Available from. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf.
3. Shankar G., Arkin S., Cocea L., Devanarayan V., Kirshner S., Kromminga A., et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014, 16(4):658-673.
4. EMA Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use Available from. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf.
5. ICH ICH harmonized tripartite guideline. Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1) 2011 Available from. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf.
6. Blacklock J.B., Wright D.C., Dedrick R.L., Blasberg R.G., Lutz R.J., Doppman J.L., et al. Drug streaming during intra-arterial chemotherapy. J Neurosurg 1986, 64(2):284-291.
7. Ionescu-Zanetti C., Khurana R., Gillespie J.R., Petrick J.S., Trabachino L.C., Minert L.J., et al. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc Natl Acad Sci U S A 1999, 96(23):13175-13179.
8. Chi E.Y., Krishnan S., Randolph T.W., Carpenter J.F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003, 20(9):1325-1336.
9. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000, 203(1-2):1-60.
10. Demeule B., Palais C., Machaidze G., Gurny R., Arvinte T. New methods allowing the detection of protein aggregates: a case study on trastuzumab. MAbs 2009, 1(2):142-150.
11. Carpenter J.F., Kendrick B.S., Chang B.S., Manning M.C., Randolph T.W. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 1999, 309:236-255.
12. Brinks V., Jiskoot W., Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 2011, 28(10):2379-2385.
13. Stewart T.A., Hollingshead P.G., Pitts S.L., Chang R., Martin L.E., Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med 1989, 6(4):275-281.
14. Whiteley P.J., Lake J.P., Selden R.F., Kapp J.A. Tolerance induced by physiological levels of secreted proteins in transgenic mice expressing human insulin. J Clin Invest 1989, 84(5):1550-1554.
15. Hermeling S., Aranha L., Damen J.M., Slijper M., Schellekens H., Crommelin D.J., et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005, 22(12):1997-2006.
16. Fradkin A.H., Carpenter J.F., Randolph T.W. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 2009, 98(9):3247-3264.
17. Lee H.J., Riley G., Johnson O., Cleland J.L., Kim N., Charnis M., et al. In vivo characterization of sustained-release formulations of human growth hormone. J Pharmacol Exp Ther 1997, 281(3):1431-1439.
18. Koren E., De Groot A.S., Jawa V., Beck K.D., Boone T., Rivera D., et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 2007, 124(1):26-32.
19. Cohen T., Moise L., Ardito M., Martin W., De Groot A.S. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J Biomed Biotechnol 2010, 2010.
20. Tatarewicz S.M., Wei X., Gupta S., Masterman D., Swanson S.J., Moxness M.S. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 2007, 27(6):620-627.
21. Gilliland L.K., Walsh L.A., Frewin M.R., Wise M.P., Tone M., Hale G., et al. Elimination of the immunogenicity of therapeutic antibodies. J Immunol 1999, 162(6):3663-3671.
22. Cousens L.P., Najafian N., Mingozzi F., Elyaman W., Mazer B., Moise L., et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2013, 33(Suppl. 1):S43-S49.
23. Cousens L.P., Su Y., McClaine E., Li X., Terry F., Smith R., et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res 2013, 2013:621693.
24. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12(3):436-443.
25. Mingozzi F., High K.A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013, 122(1):23-36.
26. Adair P., Su Y., Scott D.W. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies. Discov Med 2013, 15(84):275-282.
27. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008, 48(5):1267-1281.
28. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008, 333(1-2):1-9.
29. van Schouwenburg P.A., Bartelds G.M., Hart M.H., Aarden L., Wolbink G.J., Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010, 362(1-2):82-88.
30. Schmidt E., Hennig K., Mengede C., Zillikens D., Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 2009, 132(3):334-341.
31. Finkelman F.D. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007, 120(3):506-515. [quiz 16-7].
32. Vadas P., Gold M., Perelman B., Liss G.M., Lack G., Blyth T., et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008, 358(1):28-35.
33. Swanson S. Detection of immune complex formation in non-clinical studies and implications for clinical risk assessment 2014 Available from. http://www.e-i-p.eu/wp-content/uploads/2013/02/Steve-Swanson-EIP-symposium-2014.pdf.
34. Hunley T.E., Corzo D., Dudek M., Kishnani P., Amalfitano A., Chen Y.T., et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 2004, 114(4):e532-e535.
35. Finco D., Baltrukonis D., Clements-Egan A., Delaria K., Gunn G.R., Lowe J., et al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J Pharm Biomed Anal 2011, 54(2):351-358.
36. Jolicoeur P., Tacey R.L. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis 2012, 4(24):2959-2970.
37. Wang J., Lozier J., Johnson G., Kirshner S., Verthelyi D., Pariser A., et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 2008, 26(8):901-908.
38. Wadhwa M., Bird C., Dilger P., Gaines-Das R., Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 2003, 278(1-2):1-17.
39. Kaliyaperumal A., Pennucci J., Nagatani J., Juan G., Swanson S., Gupta S. A method to quantitate the neutralizing capacity of anti-therapeutic protein antibodies in serum and their correlation to clinical impact. J Pharm Biomed Anal 2014, 102C:176-183.
40. Gupta S., Devanarayan V., Finco D., Gunn G.R., Kirshner S., Richards S., et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal 2011, 55(5):878-888.
41. Lallemand C., Meritet J.F., Blanchard B., Lebon P., Tovey M.G. One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. J Immunol Methods 2010, 356(1-2):18-28.
42. van Schie K.A., Hart M.H., de Groot E.R., Kruithof S., Aarden L.A., Wolbink G.J., et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015, 74(1):31-315.
43. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73(3):492-509.
44. Atzeni F., Talotta R., Salaffi F., Cassinotti A., Varisco V., Battellino M., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013, 12(7):703-708.
45. Garces S., Demengeot J., Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013, 72(12):1947-1955.
46. Garces S., Antunes M., Benito-Garcia E., da Silva J.C., Aarden L., Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2014, 73(6):1138-1143.
47. Pascual-Salcedo D., Plasencia C., Ramiro S., Nuno L., Bonilla G., Nagore D., et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50(8):1445-1452.
48. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305(14):1460-1468.
49. Menting S.P., van Lumig P.P., de Vries A.C., van den Reek J.M., van der Kleij D., de Jong E.M., et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol 2014, 150(2):130-136.
50. Lecluse L.L., Piskin G., Mekkes J.R., Bos J.D., de Rie M.A. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008, 159(3):527-536.
51. Cheifetz A., Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005, 72(4):250-256.
52. Singh N., Agrawal S., Rastogi A.K. Infectious diseases and immunity: special reference to major histocompatibility complex. Emerg Infect Dis 1997, 3(1):41-49.
53. Nepom B.S. The role of the major histocompatibility complex in autoimmunity. Clin Immunol Immunopathol 1993, 67(3 Pt 2):S50-S55.
54. Caillat-Zucman S., Gimenez J.J., Wambergue F., Albouze G., Lebkiri B., Naret C., et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998, 53(6):1626-1630.
55. Poland G.A., Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001, 20(3-4):430-438.
56. Parkar B.A., Reeves W.G. In vitro priming of human lymphocytes to heterologous insulins. J Immunol Methods 1989, 120(2):159-165.
57. Palleroni A.V., Aglione A., Labow M., Brunda M.J., Pestka S., Sinigaglia F., et al. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997, 17(Suppl. 1):S23-S27.
58. Wang P., Sidney J., Dow C., Mothe B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008, 4(4):e1000048.
59. Benatuil L., Kaye J., Rich R.F., Fishman J.A., Green W.R., Iacomini J. The influence of natural antibody specificity on antigen immunogenicity. Eur J Immunol 2005, 35(9):2638-2647.
60. Steenholdt C., Palarasah Y., Bendtzen K., Teisner A., Brynskov J., Teisner B., et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013, 37(12):1172-1183.
61. Coutinho A., Kazatchkine M.D., Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995, 7(6):812-818.
62. Madi A., Bransburg-Zabary S., Kenett D.Y., Ben-Jacob E., Cohen I.R. The natural autoantibody repertoire in newborns and adults: a current overview. Adv Exp Med Biol 2012, 750:198-212.
63. Stewart J., Varela F.J., Coutinho A. The relationship between connectivity and tolerance as revealed by computer simulation of the immune network: some lessons for an understanding of autoimmunity. J Autoimmun 1989, 2:15-23. [Suppl.].
64. Ragnhammar P., Friesen H.J., Frodin J.E., Lefvert A.K., Hassan M., Osterborg A., et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994, 84(12):4078-4087.
65. Davis T.A., Grillo-Lopez A.J., White C.A., McLaughlin P., Czuczman M.S., Link B.K., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18(17):3135-3143.
66. Piro L.D., White C.A., Grillo-Lopez A.J., Janakiraman N., Saven A., Beck T.M., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999, 10(6):655-661.
67. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52(9):2740-2750.
68. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50(8):2580-2589.
69. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41(9):1552-1563.
70. Baert F., Noman M., Vermeire S., Van Assche G., DH G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348(7):601-608.
71. Jani M., Barton A., Warren R.B., Griffiths C.E., Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014, 53(2):213-222.
72. Messinger Y.H., Mendelsohn N.J., Rhead W., Dimmock D., Hershkovitz E., Champion M., et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012, 14(1):135-142.
73. Kubisz P., Plamenova I., Holly P., Stasko J. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy. Med Sci Monit 2009, 15(6):CS105-CS111.